Drug Company Abbott Picks Singapore for Trial of New Cancer Drug (Singapore)
This article was originally published in PharmAsia News
Abbott has recently completed successful Phase I trials of a new cancer drug in Singapore. The company has also announced the selection of Singapore as home to the drug's Phase II trials. Abbott Regional Director Cihangir Kosu says the company chose Singapore because of its "solid infrastructure, high quality of healthcare services, and the existence of outstanding clinical research." The Phase II trials of the drug will occur over a period of six to 18 months. The drug's effectiveness will be tested on between 40 and 60 end-stage cancer patients, as opposed to the 21 tested in the Phase I trials. The new drug works by blocking blood-flow to cancer tumors. Subjects in the Phase I trials saw reductions in tumor size, while avoiding many of the serious side effects associated with most chemotherapy treatments. (Click here for more
You may also be interested in...
The Phase III FIDELIO trial of finerenone has been a success but analysts want to see some actual data before declaring it an unqualified one.
Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.
Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.